Daiichi Sankyo, Inc. Announces Filing Of Supplemental New Drug Application For WelChol In The Treatment Of Type 2 Diabetes Mellitus

... Daiichi Sankyo, Inc. announced today that it has filed a supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration (FDA) for WelChol(R) (colesevelam HCl) to improve glycemic control in patients with type 2 diabetes mellitus. If approved, WelChol will be the first LDL cholesterol lowering medication also indicated for improving glycemic control. [click link for full article] ...